Clinical Trial

Individualized Tumor Specific TCR- T Cells in the Treatment of Advanced Solid Tumors

Recruiting Phase 1
View on ClinicalTrials.gov →
Record status
This record was last updated September 19, 2024 (before its estimated October 1, 2025 completion). Its status may not reflect the trial's current state.
Summary
The primary purpose of this study is to evaluate the safety of the tumor-specific TCR-T cells in the treatment of advanced Solid Tumor . The secondary purpose of this study is to preliminarily showed the effect of TCR-T cells in the treatment of advanced Solid Tumor .
Protocol Amendment History 8 amendments
This ClinicalTrials.gov record has been amended 8 times since 2019-03-25; most recent amendment 2024-09-13.
Trial Details
NCT Number NCT03891706
Lead Sponsor Guangzhou FineImmune Biotechnology Co., LTD.
Collaborators: Sun Yat-Sen University Cancer Center
Conditions Solid Tumor
Enrollment 30 participants
Start Date 2019-01-08
Primary Completion 2025-10-01 (estimated)
Study Completion 2025-12-31 (estimated)
Updated on ClinicalTrials.gov 2024-09-19